134 related articles for article (PubMed ID: 12860962)
21. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries.
Freyhardt P; Zeller T; Kröncke TJ; Schwarzwaelder U; Schreiter NF; Stiepani H; Sixt S; Rastan A; Werk M
Rofo; 2011 May; 183(5):448-55. PubMed ID: 21274828
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
26. [A case of advanced gastric cancer treated with weekly paclitaxel with measurement of paclitaxel concentrations in blood and ascites].
Kojima T; Matsui T; Uemura T; Fujimitsu Y; Kato J; Kojima H
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1529-31. PubMed ID: 14584291
[TBL] [Abstract][Full Text] [Related]
27. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
Sparreboom A; Baker SD; Verweij J
J Clin Oncol; 2005 Nov; 23(31):7765-7. PubMed ID: 16258080
[No Abstract] [Full Text] [Related]
29. A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel.
Marsh RE; Tuszyński JA; Sawyer M; Vos KJ
Math Biosci Eng; 2011 Apr; 8(2):325-54. PubMed ID: 21631133
[TBL] [Abstract][Full Text] [Related]
30. Dose-intense paclitaxel: deja vu all over again?
Takimoto CH; Rowinsky EK
J Clin Oncol; 2003 Aug; 21(15):2810-4. PubMed ID: 12807932
[No Abstract] [Full Text] [Related]
31. Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
Dhanikula RS; Dhanikula AB; Panchagnula R
Pharmazie; 2008 Jun; 63(6):439-45. PubMed ID: 18604987
[TBL] [Abstract][Full Text] [Related]
32. Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target.
Egorin MJ
J Clin Oncol; 2003 Jan; 21(2):182-3. PubMed ID: 12525507
[No Abstract] [Full Text] [Related]
33. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
[TBL] [Abstract][Full Text] [Related]
34. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
Smorenburg CH; Sparreboom A; Bontenbal M; Stoter G; Nooter K; Verweij J
J Clin Oncol; 2003 Jan; 21(2):197-202. PubMed ID: 12525510
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
[TBL] [Abstract][Full Text] [Related]
38. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration.
Soma D; Kitayama J; Ishigami H; Kaisaki S; Nagawa H
J Surg Res; 2009 Jul; 155(1):142-6. PubMed ID: 19328496
[TBL] [Abstract][Full Text] [Related]
39. Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs.
Zhao L; Ye Y; Li J; Wei YM
J Pharm Pharmacol; 2011 Jan; 63(1):80-6. PubMed ID: 21155819
[TBL] [Abstract][Full Text] [Related]
40. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
